scholarly journals Pelvic radiotherapy for cervical cancer affects importantly the reproducibility of cytological alterations evaluation

2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Fernanda A. Lucena ◽  
Ricardo F. A. Costa ◽  
Maira D. Stein ◽  
Carlos E. M. C. Andrade ◽  
Geórgia F. Cintra ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Pelvic Radiotherapy ◽  
Cytological Alterations

scholarly journals Association between the location of transposed ovary and ovarian dose in patients with cervical cancer treated with postoperative pelvic radiotherapy

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Xiao-juan Lv ◽  
Xiao-long Cheng ◽  
Ye-qiang Tu ◽  
Ding-ding Yan ◽  
Qiu Tang
Keyword(s):  
Cervical Cancer ◽  
Radical Hysterectomy ◽  
Adjuvant Radiotherapy ◽  
Iliac Crest ◽  
Ovarian Function ◽  
Pelvic Radiotherapy ◽  
Cutoff Value ◽  
Ovarian Transposition ◽  
Transverse Distance ◽  
Upper Boundary

Abstract Background and purpose How to protect the ovarian function during radiotherapy is uncertain. The purpose of this study was to explore the association between the location of the transposed ovary and the ovarian dose in patients with cervical cancer received radical hysterectomy, ovarian transposition, and postoperative pelvic radiotherapy. Methods A retrospective analysis was conducted of 150 young patients with cervical cancer who received radical hysterectomy, intraoperative ovarian transposition, and postoperative adjuvant radiotherapy in Zhejiang Cancer Hospital. Association between location of the transposed ovaries and ovarian dose was evaluated. The transposed position of ovaries with a satisfactory dose was explored using a receiver operator characteristic curve (ROC) analysis. Patients’ ovarian function was followed up 3 months and 1 year after radiotherapy. Results A total of 32/214 (15%) transposed ovaries were higher than the upper boundary of the planning target volume (PTV). The optimum cutoff value of > 1.12 cm above the iliac crest plane was significantly associated with ovaries above the upper PTV boundary. When the ovaries were below the upper boundary of PTV, the optimum cutoff value of transverse distance > 3.265 cm between the ovary and PTV was significantly associated with ovarian max dose (Dmax) ≤ 4Gy, and the optimum cutoff value of transverse distance > 2.391 cm was significantly associated with ovarian Dmax≤5Gy. A total of 77 patients had received complete follow-up, and 56 patients (72.7%) showed preserved ovarian function 1 year after radiotherapy, which was significantly increased compared with 3 months (44.2%) after radiotherapy. Conclusions The location of transposed ovaries in patients with cervical cancer is significantly correlated with ovarian dose in adjuvant radiotherapy. We recommend transposition of ovaries > 1.12 cm higher than the iliac crest plane to obtain ovarian location above PTV. When the transposed ovary is below the upper boundary of PTV, ovarian Dmax ≤4Gy may be obtained when the transverse distance between the ovary and PTV was > 3.265 cm, and the ovarian Dmax≤5Gy may be obtained when the transverse distance was > 2.391 cm.

scholarly journals Definitive radiotherapy consisting of whole pelvic radiotherapy with no central shielding and CT-based intracavitary brachytherapy for cervical cancer: feasibility, toxicity, and oncologic outcomes in Japanese patients

2020 ◽  
Vol 25 (11) ◽  
pp. 1977-1984
Author(s):  
Takeaki Kusada ◽  
Takafumi Toita ◽  
Takuro Ariga ◽  
Wataru Kudaka ◽  
Hitoshi Maemoto ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Treatment Time ◽  
Treatment Protocol ◽  
Japanese Patients ◽  
Oncologic Outcomes ◽  
Intracavitary Brachytherapy ◽  
High Dose ◽  
Tumor Diameter ◽  
Pelvic Radiotherapy ◽  
Definitive Radiotherapy

Abstract Background This prospective study investigated the feasibility, toxicity, and oncologic outcomes of definitive radiotherapy (RT) consisting of whole pelvic radiotherapy with no central shielding (noCS-WPRT) and CT-based intracavitary brachytherapy (ICBT) in Japanese patients with cervical cancer. Methods Patients with cervical cancer of FIGO stages IB1–IVA were eligible. The treatment protocol consisted of noCS-WPRT of 45 Gy in 25 fractions and CT-based high dose-rate ICBT of 15 or 20 Gy in 3 or 4 fractions prescribed at point A. The prescribed ICBT dose was decreased if the manual dwell time/position optimization failed to meet organs-at-risk constraints. Graphical optimization and additional interstitial needles were not applied. Results We enrolled 40 patients. FIGO stages were IB1: 11, IB2: 13, IIA2: 1, IIB: 11, IIIB: 3, and IVA: 1. Median (range) pretreatment tumor diameter was 47 (14–81) mm. Point A doses were decreased in 19 of 153 ICBT sessions (12%). The median follow-up duration was 33 months. The 2-year rates of pelvic control, local control (LC), and progression-free survival were 83%, 85%, and 75%, respectively. Pre-ICBT tumor diameter, high-risk clinical target volume (HR-CTV), total HR-CTV D90, and overall treatment time (OTT) significantly affected LC. Late adverse events (grade ≥ 3) were observed in 3 patients (2 in the bladder, 1 in the rectum). Conclusions Definitive RT consisting of noCS-WPRT and CT-based ICBT was feasible for Japanese patients with cervical cancer. To further improve LC, additional interstitial needles for patients with a large HR-CTV and shorter OTT should be considered.

IMRT COMPARED WITH 4 FIELD CONFORMAL PELVIC RADIOTHERAPY FOR THE DEFINITIVE TREATMENT OF CERVICAL CANCER

2009 ◽  
Vol 92 ◽  
pp. S90-S91
Author(s):  
J. Forrest ◽  
J. Presutti ◽  
M. Davidson ◽  
P. Hamilton ◽  
G. Thomas
Keyword(s):  
Cervical Cancer ◽  
Definitive Treatment ◽  
Pelvic Radiotherapy

scholarly journals Pelvic Nodal CTV from L4–L5 or Aortic Bifurcation?—An Audit of the Patterns of Regional Failures in Cervical Cancer Patients Treated with Pelvic Radiotherapy

2014 ◽  
Vol 44 (10) ◽  
pp. 941-947 ◽  
Author(s):  
Bhavana Rai ◽  
Anshuma Bansal ◽  
Firuza Patel ◽  
Abhishek Gulia ◽  
Rakesh Kapoor ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Patients ◽  
Aortic Bifurcation ◽  
Pelvic Radiotherapy

scholarly journals Experiences with the Use of Vaginal Dilator by Cervical Cancer Women Who Received Pelvic Radiotherapy at Cancer Diseases Hospital, Lusaka Zambia

2021 ◽  
Vol 11 (10) ◽  
pp. 1386-1396
Author(s):  
Alex Mwale ◽  
Patricia Katowa-Mukwato ◽  
Victoria Mwiinga Kalusopa ◽  
Phadaless Phiri-Sinkamba ◽  
Susan Mutemwa
Keyword(s):  
Cervical Cancer ◽  
Pelvic Radiotherapy ◽  
Cancer Diseases

Correlation between c-erb-B2 overexpression with disease-free survival and rate of pelvic relapse in patients with advanced cervical cancer treated with chemo-radiotherapy

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 16004-16004
Author(s):  
J. Pérez-Regadera ◽  
A. Sánchez-Muñoz ◽  
J. De-la-Cruz ◽  
C. Ballestín ◽  
D. Lora ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Disease Free Survival ◽  
Concurrent Chemotherapy ◽  
Immunohistochemical Method ◽  
Advanced Cervical Cancer ◽  
Pelvic Radiotherapy ◽  
Free Survival ◽  
The Impact ◽  
Disease Free ◽  
Pelvic Relapse

16004 Aims: To determine the impact of the c-erb-B2 overexpression receptor on pelvic relapse and on disease-free survival (DFS) in patients with advanced cervical cancer receiving concurrent chemo-radiotherapy. Methods: One hundred thirty six patients with advanced cervical cancer (stage: 12 IB2-IIA, 34 IIB, 71 IIIB, 19 IVA); histology: 86 epidermoid and 14 adenocarcinoma) were analyzed to detect c-erbB-2 level using an immunohistochemical method (Herceptest Dako). Cases c-erbB-2 (+3) were considered positive. All patients received pelvic radiotherapy, brachitherapy and concurrent chemotherapy with two schedules: 48 patients with tegafur (800 mg/day via oral) and 88 with tegafur (same doses) plus five cycles of weekly cisplatin 40 mg/m2/week iv. Results: Of the 136 biopsies, 32 (23.5%) were c- erbB-2 positive. The disease free survival to 3 and 5 years of the patients were 61% and 58% for c-erb-B2 negative and 36% and 36% for c-erb- B2 positive (p=0.02), respectively.We divided our patients in four groups: c-erb-B2 positive treated with cisplatin; c-erb-B2 positive without cisplatin, c-erb-b2 negative treated with cisplatin and c-erb-b2 negative without cisplatin. The group of patients with c-erb-B2 overexpression that did not received platinum treatment had a higher rate of pelvis relapse (p<0.0001) and with a decreased DFS (p=0.0014). Conclusions: c-erbB-2 overexpression may imply a poor prognosis for patients with advanced cervix cancer, especially if they did not receive concurrent radiochemotherapy with cisplatin. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document